MedPAC projects dialysis facility margins to decrease 1.8% in 2022 as costs exceed payment updates, warns margins not enough to support hospital cost-saving products, services; study also shows in-home dialysis has risen from 24% to 29% from 2014 to 2020

Sample article from our Tissue & Hygiene

WASHINGTON, D.C. , March 21, 2022 (press release) –

Report Notes Facilities Have Increased Home Dialysis Rates to Almost 30%

Kidney Care Partners (KCP) – the nation’s largest non-profit kidney care coalition of more than 30 organizations, comprising patients, physicians, nurses, researchers, transplant coordinators, dialysis professionals, therapeutic innovators and manufacturers – today expressed concern for the viability of dialysis services following a report from the Medicare Payment Advisory Commission (MedPAC), projecting dialysis facility margins decreasing to 1.8 percent for 2022. The report notes that the projection, which includes the sequester relief through June 2022, indicates that cost changes will exceed payment updates, more than one percentage point less than the actual 2020 Medicare margin, which MedPAC found to be 2.7 percent.

“While MedPAC’s estimate shows a narrow margin of only 1.8% for 2022, it is important to note this projection does not take into account several negative environmental realities impacting infrastructure in our nation’s nearly 2,000 outpatient dialysis care settings,” said Michele Kimball, Executive Director of KCP. “The analysis does not include the impact of the recent exponential increases in labor costs due to workforce shortage problems, as well as the inflationary realities and supply chain shortages.”

In light of the narrow margin, MedPAC recommends that outpatient dialysis facilities receive the projected 1.2 percent base rate increase under current law.

“The low margins are concerning as patients anticipate the launch of innovative products into the Medicare ESRD program in 2022,” noted Kimball. “The narrow margins demonstrate that there is not sufficient funding in the ESRD base rate to support the addition of innovative products and services, especially those that generate savings on the hospital side of the program rather than within the dialysis facility. To protect patient access to innovation, we ask that the Centers for Medicare & Medicaid Services (CMS) address policy options to support sustainable reimbursement for innovative products.”

The report notes that among the in-center facilities offering home dialysis, total treatments furnished in the home have increased between 2014 and 2020 from 24 percent to 29 percent. Among those facilities in the 75th percentile, the increase was from 28 percent to 32 percent during the same period.

“KCP and its members have consistently supported efforts to address barriers to home dialysis,” said KCP Chairman John P. Butler. “This increase in patients selecting home dialysis is great progress, but more still needs to be done to address socioeconomic barriers, such as housing insecurity, the availability of care partners, and expanding patient education. We agree with the U.S. Government Accountability Office’s conclusion that payment restrictions on the type of providers who can furnish the Medicare Kidney Disease Education (KDE) benefit should be eliminated because they constrain access.”

In addition, the MedPAC report noted improvements in quality outcomes for individuals who rely upon dialysis. The all-cause hospitalization and emergency department use declined in 2020 compared to previous years.

“Improving quality remains a top priority of the KCP,” concluded Butler. “We are excited that improvements are reflected in the measures MedPAC highlights, and as a community, we will continue to work through the Kidney Care Quality Alliance to advance meaningful measures to support home dialysis and transplant.”

To read the full report from MedPAC to Congress, click here.
Contact
Kidney Care Partners
Sarah Feagan
703-543-9180
http://www.kidneycarepartners.org
ContactContact

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order tissue & hygiene coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.